| abstract |
The present invention as a monovalent dimer has a higher serum half-life compared to the native/natural molecule, thus advantageous for achieving higher titers of the protein during production, higher stability during storage, and improved efficacy when used as a therapeutic agent. Fc-fused protein constructs are provided. Also provided are Fc-fused protein constructs having mutations in the Fc region that reduce effector function, which have increased activity to inhibit tumor growth, and thus are advantageous when used as cancer therapy. |